The Truth About LDL: Why One Keto Study Doesn't Change the Heart Disease Evidence | Dr Terry Simpson

#1

I. Executive Summary

In this critical clinical synthesis, Dr. Terry Simpson and Simon Hill deconstruct emerging cardiovascular, metabolic, and neuroprotective literature, rigorously separating established epidemiological and mechanistic consensus from internet-driven nutritional hype and flawed trial interpretations. The primary focus centers on the causal role of apolipoprotein B (ApoB)-containing lipoproteins in atherogenesis and the critical re-evaluation of the longitudinal KETO-CTA trial evaluating Lean Mass Hyper-Responders (LMHR). Despite claims that metabolic health neutralizes high ApoB-driven cardiovascular risk, longitudinal CCTA data reveal that 21% to 29% of LMHR subjects exhibit rapid plaque progression (defined as a >1% annual increase in Percent Atheroma Volume [PAV]), compared to a baseline rate of ~3% in normolipidemic, metabolically healthy cohorts. Abstract-level reporting emphasizing minor non-calcified plaque “regression” (15%) represents selective outcome presentation, as true structural regression requires reductions in total plaque volume—a metric confounded by CCTA measurement noise in low-burden individuals, where repeat scans require 5-to-7-year intervals to establish signal over artifact.

In lipid management, therapeutic paradigms prioritize aggressive ApoB reduction to achieve plaque stabilization and regression (targeting ApoB < 50 mg/dL or LDL-C < 40 mg/dL). While monoclonal PCSK9 inhibitors (Evolocumab, Alirocumab) possess robust randomized controlled trial (RCT) cardiovascular outcome data, emerging oral macrocyclic peptides (MK-0616) and small-binding proteins (Lerodalcibep) demonstrate equivalent ~50–60% ApoB lowering, though long-term major adverse cardiovascular event (MACE) reduction data remain pending. In metabolic disease, stem cell-derived islet transplantation into the portal vein demonstrates functional independence from exogenous insulin in Type 1 Diabetes, with CRISPR-mediated gene editing targeting HLA expression to eliminate lifelong immunosuppression. For Type 2 Diabetes, pathophysiology dictates that ~50% of pancreatic beta-cell mass is irrevocably lost at diagnosis via endoplasmic reticulum stress and unfolded protein response apoptosis, highlighting that glycemic normalization represents clinical remission rather than anatomical reversal. Finally, public health priorities must emphasize progressive resistance training over protein supplementation alone to prevent sarcopenia, early colorectal cancer screening starting at age 45 (or 40 electively), universal Lp(a) quantification in nmol/L, and high-fiber, plant-rich dietary patterns (MIND/DASH) to reduce neurodegenerative and oncologic risk.

II. Insight Bullets

  1. ApoB Causality vs. “Cholesterol Denialism”: Apolipoprotein B (ApoB)-containing lipoproteins are causally linked to atherogenesis across observational, Mendelian randomization, and RCT data; therapeutic targeting of ApoB is driven by vascular biology rather than pharmaceutical profit motives.
  2. KETO-CTA Trial Rapid Progression Signal: Longitudinal CCTA data in Lean Mass Hyper-Responders (LMHR) demonstrate that 21% to 29% of subjects experience rapid plaque progression (>1% PAV/year), contrasting sharply with ~3% in normolipidemic matched controls (Norwitz et al., 2025).
  3. Selective Reporting and Outcome Bias in Keto Literature: Abstracts highlighting 15% non-calcified plaque “regression” rely on measurement changes within CCTA noise margins (e.g., -0.02 mm³), while obfuscating statistically significant total plaque volume progression across the majority of subjects.
  4. CCTA Imaging Noise and Measurement Limitations: In low plaque burden cohorts, AI quantitative software (Cleerly, HeartFlow, QAngio) suffers from high inter-scan measurement variability; repeat CCTA imaging requires 5-to-7-year intervals to detect real anatomical changes rather than artifact.
  5. Atheroma “Volcano” Stabilization Concept: Vascular plaques function as dynamic geological structures; aggressive therapeutic lowering of ApoB stabilizes lipid-rich cores, converting active, rupture-prone “volcanoes” into dormant, fibrous lesions.
  6. Arterial vs. Venous Atherosclerosis Pathophysiology: ApoB particles penetrate arterial walls due to high endothelial LDL receptor density, turbulent shear stress, and an extensive sub-endothelial glycocalyx that traps macrophages; veins lack these structural properties, preventing foam cell accumulation.
  7. “Plaque Begets Plaque” Fallacy: The hypothesis that baseline plaque independently drives future plaque progression without ApoB involvement misinterprets the mechanism; elevated ApoB particle flux remains the required substrate for intra-arterial lipid retention.
  8. Monoclonal Antibodies vs. Novel Oral PCSK9 Inhibitors: Injectable monoclonal antibodies (Evolocumab, Alirocumab) have verified MACE reduction outcomes in landmark RCTs (FOURIER, ODYSSEY OUTCOMES), whereas novel oral macrocyclic peptides (MK-0616) (PMID: 37815341) and small-binding proteins (Lerodalcibep) currently rely on ~50–60% ApoB surrogate marker reduction.
  9. Permanent In Vivo Gene Editing for PCSK9: Emerging CRISPR base-editing techniques (e.g., Verve Therapeutics) achieve durable (>14-month human data) inactivation of hepatic PCSK9 following single-dose delivery, presenting a potential lifelong therapeutic model.
  10. Target ApoB Thresholds for Plaque Regression: Demonstrable plaque regression and fibrous cap stabilization consistently require driving ApoB below 50 mg/dL (or LDL-C below 40 mg/dL), levels unachievable through lifestyle alone in severe hyperlipidemia.
  11. Stem Cell-Derived Islet Transplantation in Type 1 Diabetes: Allogeneic stem cell-derived islet cells transplanted into the portal vein restore endogenous insulin secretion and glycemic control (Vertex VX-880/VX-264), currently constrained by required systemic immunosuppression.
  12. CRISPR Hypoimmunogenic “Stealth” Islets: Gene editing of donor or stem cell-derived islets to disrupt HLA expression and overexpress immune checkpoints (Sana Biotech) enables long-term insulin independence without systemic immunosuppression.
  13. Type 2 Diabetes Beta-Cell Loss vs. “Reversal”: Clinical diagnosis of Type 2 Diabetes occurs only after ~50% of functional pancreatic beta-cell mass is destroyed by endoplasmic reticulum stress and unfolded protein response apoptosis; dietary remission restores metabolic control but does not regenerate lost endocrine mass.
  14. Super-Agers and Environmental Non-Genetic Determinants: Individuals over 80 with cognitive capacity equal to 20-30-year-olds demonstrate APOE2/E4 gene distributions identical to the general population, confirming lifestyle factors (vascular risk control, exercise, diet) override genetic risk.
  15. MIND Diet Neuroprotection Thresholds: High adherence to the MIND diet (combining Mediterranean and DASH principles) slows cognitive decline by an equivalent of 7.5 years (Morris et al., 2015); top-quartile adherence (>12.5/15 points) confers substantial benefit without requiring 100% adherence.
  16. Polyphenol Oxidase (PPO) Bioavailability Context: High-PPO ingredients like bananas degrade flavan-3-ols in co-ingested foods (berries/cacao) by up to 84% in acute pharmacokinetic trials (Ottaviani et al., 2023), but this effect is minor compared to overall dietary fiber and polyphenol intake.
  17. Sarcopenia Etiology: Resistance Training vs. Protein Over-Supplementation: Age-related sarcopenia stems primarily from the absence of progressive resistance exercise (mechanical tension) rather than dietary protein deficiency; over 90% of adults fail resistance guidelines while already consuming adequate baseline protein (~1.2 g/kg/day).
  18. Early-Onset Colorectal Cancer (CRC) Escalation: Incidental CRC in adults <50 has increased by ~2% annually since the 1960s, driven by ultra-processed foods, high red/processed meat consumption, and severe dietary fiber deficiency (92% of US adults fail daily targets).
  19. Colonoscopy vs. Non-Invasive Stool Screening: Colonoscopy is therapeutic and preventative by identifying and snaring precancerous adenomatous polyps (7-10 year malignant progression window), whereas stool DNA/FIT tests only detect active cancerous shedding.
  20. Universal Pediatric & Adult Lipid Screening Guidelines: 2024/2026 dyslipidemia guidelines advocate universal pediatric lipid screening at age 10 (or age 2 with FH family history) and baseline adult screening at age 19 to mitigate lifetime cumulative ApoB exposure.
  21. Universal Lp(a) Screening in Concentration Units (nmol/L): Lipoprotein(a) should be measured once per lifetime using molar concentration (nmol/L) rather than mass (mg/dL) due to extensive apolipoprotein(a) isoform size heterogeneity.
  22. Lp(a) Plaque Vulnerability Mechanism: Elevated Lp(a) (>125 nmol/L) disproportionately drives plaque instability, calcification, and thrombogenicity rather than raw plaque volume expansion.
  23. PCSK9 Inhibitor Impact on Lp(a): Monoclonal and small-molecule PCSK9 inhibitors lower circulating Lp(a) by 25% to 30%, a unique secondary benefit under investigation in hard-outcome clinical trials (e.g., HORIZON trial).
  24. Public Health Misallocation vs. Medical Innovation: Defunding core public health measures (vaccination, irrigation water sanitation) has caused resurging measles outbreaks and $5B in annual foodborne pathogen costs (E. coli, Cyclospora on leafy greens), eclipsing the population health impact of expensive targeted therapeutics.
  25. Social Media Influencer Confirmation Bias: Health influencers frequently over-interpret low-sample mechanistic studies to cater to anti-pharmaceutical or extreme dietary subcultures (e.g., carnivore/keto/anti-statin), generating commercial monetization while increasing real-world patient harm.

IV. Actionable Protocol (Prioritized)

High Confidence Tier (Level A/B Evidence)

  • ApoB & Lipid Optimization: Initiate lipid-lowering pharmacotherapy (statins, ezetimibe, or PCSK9 monoclonal antibodies [Evolocumab/Alirocumab]) for individuals with elevated ApoB (>100 mg/dL) or positive Coronary Artery Calcium (CAC > 0) to target ApoB < 50 mg/dL (or LDL-C < 40–50 mg/dL) for plaque stabilization/regression.
  • Universal Diagnostic Screening:
    • Baseline Adult Lipid Panel: Complete at age 19.
    • Pediatric FH Screening: Complete universal lipid panel at age 10 (or age 2 if familial hypercholesterolemia is present).
    • Lp(a) Screening: Measure once per lifetime using molar concentration (nmol/L).
  • Colorectal Cancer Prevention & Screening:
    • Initiate screening colonoscopy at age 45 (or earlier with family history) to identify and remove precancerous polyps.
    • Consume ≥25–35g daily dietary fiber from legumes, whole grains, fruits, and vegetables to mitigate oncologic risk.
  • Sarcopenia Prevention: Complete progressive resistance training 2–3 times per week targeting major muscle groups to stimulate muscle protein synthesis through mechanical tension; maintain baseline dietary protein intake at 1.2–1.6 g/kg/day.
  • Neuroprotective Dietary Pattern: Adhere to the MIND/DASH diet structure (high fruit/berry intake, dark leafy greens, legumes, whole grains, monounsaturated fats like extra virgin olive oil; limited red/processed meats and ultra-processed foods) to delay cognitive decline.

Experimental Tier (Level C/D Evidence / Emerging Biomarkers)

  • Novel Oral PCSK9 Inhibitors: Consider oral macrocyclic peptide PCSK9 inhibitors (e.g., MK-0616) or small-binding proteins (Lerodalcibep) as alternatives to injectable monoclonal antibodies when oral delivery is required for adherence, acknowledging MACE outcome trials are ongoing.
  • CCTA Plaque Surveillance Spacing: For individuals with minor non-calcified plaque monitoring disease progression, space repeat CCTA scans 5 to 7 years apart to avoid misinterpreting software measurement noise as structural plaque change.
  • Elective Non-Invasive Screening: Utilize stool FIT/sDNA testing starting at age 40 if colonoscopy access is financially or logistically restricted.

Red Flag Zone (Debunked Claims / Safety Data Absent)

  • Ketogenic Diet Hyperlipidemia “Exemption”: Dismissing severe ApoB/LDL-C elevations (>190 mg/dL) under the “Lean Mass Hyper-Responder” hypothesis. Metabolic health does not neutralize ApoB-mediated plaque progression.
  • Waiting for CAC > 0 Before Lipid Treatment: Delaying statin or combination lipid-lowering therapy until calcified plaque is detectable on CAC scan. CAC represents late-stage calcification; waiting for CAC > 0 allows decades of unmitigated non-calcified plaque accumulation.
  • Isolated High-Dose Protein for Sarcopenia: Increasing protein supplementation without progressive resistance training to reverse age-related muscle loss (“Safety Data Absent” for anabolic efficacy in sedentary states).
1 Like